Regeneron Pharmaceuticals, Inc. (REGN) reported additional positive results from a phase 3 trial, which assessed use of a single dose of investigational REGEN-COV to prevent COVID-19. REGEN-COV reduced the risk of contracting COVID-19 by 81.6% during the pre-specified follow-up period of months 2-8, maintaining the 81.4% risk reduction during the first month after administration previously reported.
"In this trial, a single dose of REGEN-COV provided long-term protection against COVID-19, including times of particularly high risk from household exposure, and in the longer-term during ongoing broader exposure," said George Yancopoulos, President and Chief Scientific Officer at Regeneron.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.